On the Occasion of Its General Meeting, France Biotech Appoints Four New Members on Its Board of Directors and Amends Its

  • to welcome venture capitalists as active member
  • to create a college for associates members and correspondents

PARIS--(BUSINESS WIRE)-- Following its Annual General Meeting, held on Thursday 24th June, in Paris, France Biotech, the French life sciences industry association (www.france-biotech.org), reappointed its Board of Directors and amended its Statutes. Gilles Avenard, MD, (BioAlliance Pharma), Franck Grimaud (Vivalis), and Loïc Maurel , MD, (ExonHit Therapeutics) are reelected as Members of the Board.

France Biotech appoints four new members of its Board of Directors: Arnaud Constant, Pierre-Olivier Goineau, Dr Alain Munoz and Franck Zal.

France Biotech also amended its statutes to widely represent innovative life science companies by:

  • welcoming venture capitalists as active member;
  • creating of a college for associates members and correspondents to give them voting rights at the 2010 General Meeting.

"We are pleased to welcome Arnaud Constant, Pierre-Olivier Goineau, Dr Alain Munoz and Franck Zal in France Biotech’s Board of Directors and to extend our association to the entire actors of the biotech industry. We intend to carry on our actions and initiatives for innovation, research and the development of our industry thanks to a great and dynamic network where we are gathering more than 150 members”, stated André Choulika, France Biotech’s Chairman.

Composition of France Biotech's Administrative Council

 

Chairman

André Choulika, CEO of the Cellectis Group
 

Members of the new Board of Directors

Gilles Avenard, MD, (BioAlliance Pharma)

Loïc Maurel, MD, (ExonHit Therapeutics)

Philippe Pouletty, MD, (Truffle Capital, Deinove, Splicos)
Pascale Altier (Institut Pasteur)
Philippe Berthon (Aurgalys)
Thierry Bourbié (Pharmaleads)
Lison Chouraki (Commissaire aux Comptes)
Michel Finance (Neovacs)
Franck Grimaud (Vivalis)
Bertrand Mérot (LFB)
Christian Policard (Biotech Développement Conseils)
Dinah Weissmann (Biocortech)
Franck Zal (Hemarina)
Alain Munoz (Novagali Pharma)
Pierre-Olivier Goineau (ERYtech Pharma)
Arnaud Constant (Cabinet Savin & Martinet)
 

Honorary Chairman (life members of the Administrative Council)

Philippe Pouletty MD (Truffle Capital, Deinove, Splicos)

About France Biotech

France Biotech (www.france-biotech.org) is the French association of life science businesses and their partners. Its mission is to help the French life science industry to achieve a leading position in Europe. France Biotech is a driving force for change; it lobbies public authorities, economic organizations, academic research, the media and, particularly, the investor community in order to encourage the emergence of biotechnology as a top-priority, hi-tech industry and to improve the economic, legal, regulatory and managerial environment of these businesses. France Biotech currently has 150 members. The association's corporate members account for the vast majority of the investments, employees and innovative products in France's life science sector.



CONTACT:

Press:
France Biotech
Haude Costa
[email protected]
+33 (0)1 56 58 10 70
+33 (0) 6 84 25 88 27
or
Alize Public Relations
Caroline Carmagnol
[email protected]
+33 (0)6 64 18 99 59
or
Juliette Vandenbroucque
[email protected]
+33 1 42 68 86 41

KEYWORDS:   Europe  France

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.